For autoimmune conditions like type 1 diabetes to progress, selfreactive CD8 + T cells would need to interact with peptide-antigen cross-presented on the surface of antigen-presenting cells in a major histocompatibility complex (MHC) class I-restricted fashion. However, the mechanisms by which autoantigen is cross-presented remain to be identified. In this study, we show cross-presentation of islet-derived autoantigens by B cells. B cells engage self-reactive CD8 + T cells in the pancreatic lymph node, driving their proliferative expansion and differentiation into granzyme B + interferon-g + lysosomal-associated membrane protein 1 + effector cells. B-cell cross-presentation of insulin required proteolytic cleavage and endosomal localization and was sensitive to inhibitors of protein trafficking. Absent B-cell MHC class I, or B-cell receptor restriction to an irrelevant specificity, blunted the expansion of self-reactive CD8 + T cells, suggesting B-cell antigen capture and presentation are critical in vivo events for CD8 activation. Indeed, the singular loss of B-cell MHC class I subverted the conversion to clinical diabetes in NOD mice, despite the presence of a pool of activated, and B cell-dependent, interleukin-21-expressing Vb4 + CD4 + T cells. Thus, B cells govern the transition from clinically silent insulitis to frank diabetes by cross-presenting autoantigen to self-reactive CD8 + T cells.
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For autoimmune conditions like type 1 diabetes to progress, selfreactive CD8 + T cells would need to interact with peptide-antigen cross-presented on the surface of antigen-presenting cells in a major histocompatibility complex (MHC) class I-restricted fashion. However, the mechanisms by which autoantigen is cross-presented remain to be identified. In this study, we show cross-presentation of islet-derived autoantigens by B cells. B cells engage self-reactive CD8 + T cells in the pancreatic lymph node, driving their proliferative expansion and differentiation into granzyme B T here is good evidence that CD8 + cytotoxic T lymphocytes (CTL) subsequently kill b-cells, resulting in type 1 diabetes (T1D). CD8 + T-cell clones isolated from pancreatic infiltrates of NOD mice, a spontaneous diabetes model (1) , recognize defined islet autoantigens including insulin (2) , the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) (3), glutamic acid decarboxylase proteins (4) , and dystrophia myotonica kinase (5) . Defined CD8 + T-cell clones are sufficient to precipitate diabetes (6-9); conversely, CD8 + T-cell depletion (10) , inhibition of CD8 + T-cell maturation (11) , disabling CD8-effector pathways (12), or deleting surface major histocompatibility complex (MHC) class I from b-cells (13, 14) prevents clinical diabetes. Understanding CTL responses is of high clinical relevance, as MHC class I-restricted T cells reactive to insulin, IGRP, and glutamic acid decarboxylase have been identified in human subjects with T1D (4, 15, 16) . Therefore, the steps governing the activation of self-reactive CTL would represent critical nodes for intervention; nevertheless, the physiological processes that drive these events remain poorly understood.
In the NOD mouse model, B-cell depletion prevents diabetes (17) (18) (19) (20) (21) . We were intrigued by the observation that in some studies, B-cell depletion postinsulitis was protective, but also that B-cell depletion coincided with decreased CD8 + T cell activation (17, 22) . These observations suggested that targeting B cells prevented a late pathogenic event, such as CD8 + T cell-mediated b-cell destruction, and raised the possibility of a direct link between B cells and activation of self-reactive CD8 + T cells (23) . B-cell depletion delays diabetes in man (24) , indicating B cells as therapeutic targets for the treatment of type 1 diabetes (18) ; however, the mechanisms of action by which B-cell reduction effects diabetes progression are unclear. This background led us to investigate whether there was a requirement for B cells in the activation, expansion, and effector development of pathogenic CD8 + T cells and the subsequent transition to overt diabetes in the nonobese diabetic (NOD) model of spontaneous diabetes. (10-3.6) , and Vb4 T-cell receptor (KT4). Isotype controls were: immunoglobulin G (IgG) 1, l; IgG1, k, IgG2b, k, and IgG2a, k; and B cells (29) were: IgM (11/41), B220/ CD45R (RA-6B2), CD21/CD35 (7G6), CD23/Fc RII (B3B4), CD86 (B7-2) (GL1), and CD80 (B7-1) (16-10A1) (BD Biosciences). IGRP [206] [207] [208] [209] [210] [211] [212] [213] [214] (H-2K   d   /VYLKTNVFL)  and TUM (H-2K d /KYQAVTTTL) tetramers were generated at the National Institutes of Health Tetramer Core Facility (Atlanta, GA) with peptides from Mimotope. Intracellular proteins used were: interferon-g (IFN-g) (XMG1.2; BD Pharmingen), granzyme B (GB11; BD Pharmingen), CD107 (1D4B; BD Pharmingen), and interleukin (IL)-21 (BAF594; R&D Systems). Flow cytometric analysis was conducted on an FACSCalibur flow cytometer (BD Biosciences). Mixed bone marrow chimeras. For B-cell reconstitution, NOD.mMT mice (5 to 6 weeks old) were irradiated (600 rad, 32) and 24 h later reconstituted with 5 3 10 6 T cell-depleted syngeneic bone marrow cells admixed with 5 3 10 6 magnetic-activated cell sorting-purified splenic NOD B cells (B Cell Isolation Kit II; Miltenyi Biotec). For reconstitution with NOD.b 2 m 2/2 B cells, recipients received rabbit anti-asialo GM1 (Wako BioProducts, Richmond, VA). The bone marrow-B-cell chimeras are referred to as NOD.mMT + NOD B cells or NOD.mMT + NOD.b 2 m 2/2 B-cell mice, respectively. B-cell depletion. NOD mice were administered 150 mg of B-cell maturation antigen (BCMA)-Fc or 150 mg of intravenous globulin (HuIvIg; Bayer Australia) twice weekly from 9-15 weeks of age (12 injections); dosing is based upon Mariño et al. (22) and Pelletier et al. (30) . BCMA-Fc was sourced from Dr. S. Kalled (Biogen IDEC, Boston, MA). Immunization and in vitro T-cell proliferation. NOD mice were immunized with 100 mg of IGRP 206-214 peptide (Mimotopes) in Freund's complete adjuvant, and lymphocytes from draining LN were harvested at day 10. A total of 2.5 3 10
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T cells was cocultured with 2.5 3 10 5 irradiated (2,000 rad) B cells, loaded or not with IGRP 206-214 (0.1 mg/mL for 1 h at 37°C) in 96-well round-bottom plates in complete RPMI 1640 (Invitrogen Life Technologies) supplemented with 10 U/mL recombinant human IL-2 for 6 days. T-cell proliferation was measured by 5-(and 6-)carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution. To prepare stimulators, purified NOD B cells were loaded with 10 mg/mL of insulin for 2 h in serum-free RPMI at 37°C, fixed with 4% paraformaldehyde, quenched in 0.06% Gly-Gly solution (Sigma-Aldrich), and washed with cold PBS. For some experiments, B cells were pretreated with brefeldin A (BFA; 5 mg/mL; Cell Signaling Technology), primaquine (200 mg/mL), chloroquine (100 mg/mL), or lactacystine (20 mg/mL) (Sigma-Aldrich) 30 min prior and throughout loading with 10 mg/mL of insulin.
Immunofluorescence. B cells were pulsed from 5 to 120 min with 10 mg/mL fluorescein isothiocyanate (FITC)-labeled insulin (I12269; Invitrogen), with or without chloroquine (100 mg/mL) or primaquine (200 mg/mL), and then chased for 15 min with medium. Endosomes were identified by labeling for early endosomal Ag 1 (EEA1) (C45B10; Cell Signaling Technology), and nuclei were identified by DAPI stain (Invitrogen) using an IX71 microscope and analySIS software (Olympus). For quantitative analysis of insulin/endosome colocalization, the fluorescence intensity of individual insulin-positive and EEA1-positive endosomes was calculated with CellF software (Olympus). Statistical analysis. P values were calculated with the Student t test (GraphPad Prism Software; GraphPad); diabetes incidence data were plotted as Kaplan-Meier curves analyzed using the log-rank (Mantel-Cox) method with two degrees of freedom (GraphPad Prism Software; GraphPad).
RESULTS
Expansion of self-reactive CD8
+ T cells in B-celldeficient mice. The frequencies of self-reactive CD8 + T cells were tracked in four models: spontaneously diabetic NOD mice, B cell-deficient female NOD.mMT mice that do not develop diabetes (Fig. 1A) , NOD.mMT mixed bone marrow-B-cell chimeras reconstituted with NOD B cells (NOD.mMT + NOD B cells), and NOD mice treated with the B cell-depleting agent BCMA-Fc (22, 31) . For utility, we tracked IGRP-reactive CD8 + T cells that represent an isletantigen-specific pathogenic CD8 + T-cell clone (9) . IGRPreactive CD8 + T cells were readily detected in the pancreatic LN (PLN) of 16-week-old NOD mice but not NOD.mMT mice (Fig. 1B and C) . NOD.mMT + NOD B cell mice showed diabetes onset with a kinetic and penetrance similar to that of NOD mice (Fig. 1A) and, significantly, high frequencies and numbers of IGRP-reactive CD8 + T cells in PLN ( Fig. 1B and  C) . Administration of the B cell-activating factor of the tumor necrosis factor family and a proliferation-inducing ligand antagonist BCMA-Fc to NOD mice from 9-15 weeks of age (for a total of 12 injections) reduced absolute B-cell numbers in the periphery (Fig. 1D) (22, 31) and prevents diabetes (32) . Compared with control PBS-treated NOD mice, IGRPreactive CD8 + T cells were significantly reduced in BCMA-Fctreated mice at 16 weeks of age ( Fig. 1E and F) as well as the spleen and pancreas (data not shown). Thus, B cells are necessary for the postinsulitic expansion of self-reactive CD8 + T cells and the subsequent transition to hyperglycemia in spontaneously diabetic NOD mice. Where expansion of self-reactive CD8 + T cells occurs. To determine the loci where B cell-dependent expansion of self-reactive CD8 + T cells occurred, NOD8.3 CD8 + T cells were adoptively transferred into either NOD mice or NOD.mMT mice. Four days after transfer, the frequency of IGRP-reactive CD8 + T cells in peripheral lymphoid compartments was analyzed by flow cytometry. Fig. 2A shows that IGRP-reactive CD8 + T cells preferentially accumulate in the PLN of NOD mice and to a lesser extent in the pancreas but not the noninvolved inguinal LN ( Fig. 2A) . In the absence of B cells, the expansion of IGRP-reactive CD8 + T cells within the PLN was reduced, whereas the pancreatic accumulation was unperturbed.
B cell-dependent expansion of IGRP-reactive CD8 + T cells in the PLN might be the result of enhanced proliferation after an encounter with B cells. To test this, CFSElabeled NOD8.3 CD8 + T cells were adoptively transferred into either NOD or NOD.mMT mice, and proliferation was assessed by dilution of CFSE 3 days posttransfer (Fig. 2B) . It can be seen that expansion of IGRP-reactive CD8 + T cells in the PLN was due to a robust proliferative response. Relatively few transferred cells were found in the pancreas and inguinal LN ( Fig. 2A ), making it difficult to determine their proliferative history under these conditions. Of note, very little proliferation of NOD8. 2/2 NOD B cells were neither able to support CD8 + T cell proliferation nor expand IGRP-specific CD8 + T cells ( Fig. 4A and B) . Further to this, by comparing background levels of proliferation observed for CD8 + T cells alone, it could be seen that purified NOD B cells were able to drive some CD8 + T-cell (Fig. 4A) . Presumably in this case, isolated NOD B cells were displaying distinct endogenously captured autoantigens on the cell surface in the context of MHC class I molecules. In contrast, CD8 + T cells cocultured with b 2 m 2/2 NOD B cells exhibited a significantly reduced proliferative response (Fig. 4A) . B cells present autoantigen via the classical pathway. For presentation via the classical MHC class I pathway proteins can be catabolized in the proteosome to be loaded onto MHC class I molecules in the endoplasmic reticulum (ER). To further examine the intracellular trafficking routes used by B cells to present autoantigen, NOD B cells were pulsed with insulin, a prominent islet autoantigen (33) , and subsequently treated with inhibitors that would compromise the classical routes of antigen transport (34, 35) . Proliferation of self-reactive CD8 + T cells was determined as a measure of antigen presentation. Presentation of insulin to self-reactive CD8 + T cells was markedly reduced when B cells were pretreated with BFA (Fig. 4C) . BFA blocks protein transport from the ER, indicating that MHC class I loading of insulin peptides was occurring in the ER. To determine if the proteosome was required for processing of insulin, B cells were treated with the proteosome inhibitor lactacystin prior to loading with insulin. In this case, NOD B cells were less efficient drivers of CD8 + T-cell proliferation (Fig. 4D) . These data show that B-cell processing and presentation of an intact exogenous autoantigen, namely insulin, uses mechanisms shared by the endogenous classical MHC class I-restricted pathway. B-cell cross-presentation uses early endosomes. Presentation of exogenous insulin by B cells infers crosspresentation. Some data show that exogenous soluble antigens indicated for cross-presentation are directed to distinct early endosomes within APCs (34, 35) . When pulsed with fluorescently labeled insulin, B cells rapidly become FITC-positive, and labeling becomes more intense with time (Fig. 5A) . Visualization studies showed that at 10 min, FITClabeled insulin colocalized with EEA1-positive endosomes (Fig. 5B) . EEA1 colocalization indicated that once internalized, insulin was directed to early endosomes. Endosomal localization was critical for cross-presentation, as the proliferation of self-reactive CD8 + T cells was reduced when B cells were treated with lysosomotropic agents that interfere with endosomal acidification and presumably hinder proteases required for processing, namely chloroquine (Fig. 5C ) and primaquine (Fig. 5D) . Importantly, these inhibitors neither affected FITC-labeled insulin uptake by B cells (Fig. 5E ) nor superficial MHC class I expression (35 + T cells residing in the PLN of B cell-deficient NOD.mMT mice (Fig. 6A and B) . Further, IGRP-reactive CD8 + T cells in the PLN of B cell-sufficient NOD mice showed higher levels of the cytotoxic granule protein lysosomal-associated membrane protein 1 (Lamp1)/CD107 after peptide stimulation (Fig. 6C) . These data show that B cells engage self-reactive CD8 + T cells in the PLN and promote their proliferative expansion and effector differentiation. (Fig. 7A ) nor invade the pancreas (data not depicted). Further, there was a general reduction in the overall frequency of CD8 + T cells exhibiting features of antigen activation, indicated by decreased frequencies of CD8 + T cells expressing high levels of CD44 (Fig. 7B) . Thus, in the singular absence of MHC class I-bearing B cells, there was a selective decrease in the frequency of self-reactive CD8 + T cells in vivo. Loss of B-cell receptor specificity prevents CD8 expansion. The requirement for B-cell cross-presentation in vivo raised the question as to the mechanism for antigen acquisition by B cells. We examined the frequencies of IGRP + CD8 + T cells in NOD.IgHEL mice. NOD.IgHEL mice harbor a B-cell receptor repertoire restricted to the irrelevant antigen hen egg lysozyme (36) . Compared with NOD mice, NOD.IgHEL mice showed only a low accumulation of IGRP-reactive CD8 + T cells in the spleen and PLN at 16 weeks of age (Fig. 7C) . Previous studies show that NOD. IgHEL mice are resistant to diabetes (1). Thus, the ability of B cells to present MHC class I/peptide complexes to CD8 + T cells is dependent on the capacity of certain clones to capture islet cell proteins through specific membranebound Ig molecules. B-cell surface MHC class I is necessary for diabetes.
We next tested what was the importance of B cell-dependent presentation to self-reactive CD8 + T cells in the context of diabetes progression. To do this, we followed diabetes incidence in mixed bone marrow-B-cell chimeras 2/2 B cell-reconstituted NOD.mMT mixed BM-B-cell chimeric mice did not convert from clinically silent insulitis to overt diabetes as indicated by the complete absence of hyperglycemia in these cohorts (Fig. 7D) . Thus, B-cell presentation of MHC class/peptide complexes is an absolute requirement for diabetes progression in the NOD mouse.
Role of CD4
+ T-cell help in CD8 expansion. B cells can present self-antigen-MHC complexes to CD4 + T cells (1) that in turn produce cytokines including IL-21, supporting the expansion and activation of self-reactive CD8 + T cells (28, 37) . What was the role of CD4 + T cells in the context of B-cell cross-presentation to CD8 + T cells? Utilizing Vb4 and CD44 as markers for antigen-activated self-reactive CD4 + T cells in the PLN (38), we found that B cells were required for the expansion of self-reactive Vb4
+ T cells, (Fig. 8A ) and the elaboration of IL-21 (Fig. 8B) . Significantly, the ability of B cells to activate CD4 + T cells was not impaired by B cells lacking surface MHC class I (Fig. 8A-C) . Thus, in the absence of MHC class I-expressing B cells,
CD8
+ T-cell activation is impaired, and diabetes is prevented despite the presence of a substantial pool of selfreactive and activated CD4 + T cells.
DISCUSSION
In this study, we show that B cells present MHC class Ipeptide complexes to self-reactive CD8 + T cells. B-CD8 T-cell presentation of islet autoantigen results in the proliferative expansion of self-reactive CTL in the PLN and the acquisition of a cytotoxic phenotype consistent with a capacity to kill b-cells. These data support a model in which B cells govern the transition from clinically silent insulitis to overt diabetes by controlling the expansion and development of self-reactive CTL. This concept is most strongly supported by our finding that the selective loss of B-cell surface MHC class I results in failed CTL expansion and protection from diabetes. Significantly, these data provide a plausible mechanistic explanation for the diabetes resistance observed for B cell-deficient NOD.mMT mice (25) as well as NOD mice treated with B cell-depleting agents (17) (18) (19) (20) (21) , but also the improvement in diabetes observed in human subjects with T1D treated with rituximab (24) .
B cells can present islet autoantigens to self-reactive CD4 + T cells (1) , and in NOD mice in which B cells lack MHC class II, diabetes development is prevented (39) . Activated self-reactive CD4 + T cells could directly target b-cells for killing (40) but also aid and support the anti-islet CD8 + T-cell response by sustaining CD8 + T-cell survival in the pancreas (41) or by elaborating cytokines such as IL-21 enhancing CD8 + T-cell proliferation and differentiation (28, 37, 42) . Different to this scenario, our data illuminate an alternate, direct mechanism whereby B cells provide cognate help to self-reactive CD8 + T cells independent of CD4 + T-cell help. One critical consequence stemming from direct B-CD8 + T-cell interactions is the acquisition of cytolytic CD8 + T-cell effector function shown by increased IFN-g and granzyme B expression.
Some data suggest that B cells are not required for CTL activation (43) . This is observed primarily in situations in which self-reactive CTL numbers are artificially expanded such as by adoptive transfer (7) or through T-cell receptor transgenic systems (8, 9, 43) . However, in the spontaneous and unmanipulated NOD model, B-cell depletion correlates with a reduced frequency of activated CD8 cells, demonstrating the natural importance of B-CD8 T-cell interactions. The dominance of B-CD8 T-cell interactions in NOD mice may stem from a combined deficiency in APC function (44) and impaired B-cell selection (27, 45) , whereby expanding B-cell numbers (29) could capture limiting amounts of self-antigen to effectively out compete other APCs for CD8 T-cell attention. This dominance of B-cell presentation may shift antigen presentation away from other APC types that engender regulatory T cells that control autoimmunity (22) . Thus, in the natural progression of spontaneous diabetes, the special role of B cells is to expand and activate self-reactive CTL to sufficient status to enable b-cell killing and alter T-cell activation from one promoting regulation to autoimmunity.
Typically, DCs are considered the most relevant APCs for cross-presenting antigen to CTLs (46) and, consistent with this concept, exhibit the machinery required for the routing and loading of exogenous antigens onto MHC class I molecules (34, 35) . Some data indicate B cells can also cross-present exogenous antigen, which, under resting conditions, results in CTL tolerance (47) , though under inflammatory conditions, B-CD8 + T-cell interactions can lead to CTL activation (48) . This difference may be a key point, as NOD mice harbor a pool of self-reactive B cells that exhibit an activated phenotype (1). Our data map out the intracellular routes traversed by autoantigen within B cells; indeed, these data collectively show that B-cell cross-presentation of islet antigens requires surface MHC class I, localization of antigen to early endosomes, protein cleavage, and traverses exocytic trafficking routes. Cross-presentation of exogenous proteins by DCs is achieved by shuttling proteins into spatially distinct endosomes (34, 35) . This mechanism appears to be available to B cells, and our data suggest surface immunoglobulin specific for islet antigens may target the entry of autoantigens, including insulin, into early endosomes from which it can be processed for cross-presentation to self-reactive CTL.
Our data identify B cells as a central cellular foci driving diabetes progression by providing cognate help to pathogenic self-reactive CTLs. This does not exclude a role for DCs, indeed DCs and B cells may perform specific roles at spatially distinct pathogenic phases of disease. Different to B cells, DCs may contribute to the initial activation of CTL (49) as the early activation of pathogenic T cells in NOD mice does not appear to require B cells (50) , and B-cell depletion in NOD mice is most efficacious when provided after insulitis has initiated (18) . Thus, the key role played by B cells is in the amplification of the self-reactive CTL response after insulitis has been initiated, and this process is critical for the transition from clinically silent insulitis to overt diabetes. 2/2 mice were used to control for specificity. D: Cumulative data, mean 6 SEM, calculated from C.
